Abstract

Ruminants are the primary reservoir of Shiga-toxin producing Escherichia coli (STEC) O157:H7 and the main source of infection for humans. The aim of this study was to assess the immunogenic properties of a candidate vaccine consisting on the recombinant proteins of E. coli O157:H7 IntiminC280, the carboxy-terminal fraction of Intimin γ, EspB and the fusion protein between the B subunit of Stx2 and Brucella Lumazine Synthase (BLS)(BLS-Stx2B), in Holstein Fresian calves.To accomplish this goal we vaccinated calves with two doses of different vaccine formulations: 2 antigens (IntiminC280, EspB), 3 antigens (IntiminC280, EspB, BLS-Stx2B), BLS-Stx2B alone and a control non-vaccinated group. All antigens were expressed as recombinant proteins in E. coli. Specific IgG titres increased in vaccinated calves and the inclusion of BLS-Stx2B in the formulation seems to have a stimulatory effect on the humoral response to IntiminC280 and EspB after the booster. The neutralizing activity of antibodies against these two antigens was assessed in Red Blood Cell lysis assays and adherence to Hep-2 cells as a correlate of T3SS activity. Both sera from animals vaccinated with 2 or 3 antigens inhibited both virulence properties. Serological response to Stx2 was observed in animals vaccinated only with BLS-Stx2B and with 3 antigens and neutralization of Stx2 cytotoxicity was also observed in both groups. In conclusion, immunization of calves with BLS-Stx2B, IntiminC280 and EspB elicited a potent humoral response able to neutralize Shiga toxin 2 cytotoxity and the T3SS virulence properties in vitro. These results suggest that this formulation is a good candidate vaccine to reduce STEC shedding in cattle and needs to be further assessed in vivo.

Highlights

  • Enterohemorragic Escherichia coli (EHEC) O157:H7 is a major etiologic agent of diseases in humans, whose clinical spectrum includes diarrhoea, haemorrhagic colitis and haemolytic uremic syndrome (HUS), the leading cause of chronic renal failure in children in Argentina and several other countries[1, 2].Cattle are the main reservoir of EHEC O157:H7, which predominately colonizes the lymphoid follicle-dense mucosa at the terminal rectum and the rectoanal junction (RAJ)[3].E. coli O157:H7 is characterized by several virulence-associated traits which enables it to colonize the intestinal mucosa of humans and animals with a characteristic histopathological lesion known as “attaching and effacing” (A/E)

  • Similar response patterns were observed against IntiminC280 and EspB the titres against the former were higher than those observed for EspB (Fig 1)

  • The inclusion of the Brucella Lumazine Synthase (BLS)-Stx2B in the formulation seems to have a significant stimulatory effect on the IgG1 response to IntiminC280 and EspB, since a significantly higher title against both antigens was observed in the group of calves vaccinated with the 3 antigens

Read more

Summary

Introduction

Enterohemorragic Escherichia coli (EHEC) O157:H7 is a major etiologic agent of diseases in humans, whose clinical spectrum includes diarrhoea, haemorrhagic colitis and haemolytic uremic syndrome (HUS), the leading cause of chronic renal failure in children in Argentina and several other countries[1, 2]. E. coli O157:H7 is characterized by several virulence-associated traits which enables it to colonize the intestinal mucosa of humans and animals with a characteristic histopathological lesion known as “attaching and effacing” (A/E). The LEE encodes a type three secretion system (TTSS) that translocates effector proteins responsible for the A/E lesion into the host cell. A bacterial outer membrane protein, binds to Tir, the translocated Intimin receptor in the host cell membrane, and this binding leads to the formation of the A/E lesion

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call